Review
Pharmacology & Pharmacy
Malgorzata Borczyk, Marcin Piechota, Jan Rodriguez Parkitna, Michal Korostynski
Summary: This article discusses the variability of antidepressant effectiveness in treating major depressive disorder among patients, with genetic factors playing a significant role in individual responses. The integration of genomics and pharmacology can provide guidance for personalized treatment of depression.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Psychiatry
Milica Pjevac, Sara Redensek Trampuz, Tanja Blagus, Vita Dolzan, Jurij Bon
Summary: Pharmacogenetic analysis can predict individual differences in response to psychopharmacotherapy, allowing for personalized treatment and minimizing adverse drug reactions. It is important to consider the genetic variations in the cytochrome P450 enzymes that metabolize most psychotropic medications. This case report demonstrates the impact of pharmacogenetic analysis on treatment outcome in an elderly patient with severe depression.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Psychiatry
N. M. Del Toro-Pagan, A. Matos, C. Bardolia, V. Michaud, J. Turgeon, N. S. Amin
Summary: This case highlights the importance of pharmacogenomic testing and the key role of pharmacists in identifying and mitigating drug-related problems and optimizing drug therapy in patients with severe major depressive disorder (MDD).
Article
Health Care Sciences & Services
Taichi Ochi, Natalya M. Vyalova, Innokentiy S. Losenkov, Diana Z. Paderina, Ivan Pozhidaev, Anton J. M. Loonen, German G. Simutkin, Nikolay A. Bokhan, Bob Wilffert, Svetlana A. Ivanova
Summary: This study found a possible association between genotype related to dopamine neurotransmission and antidepressant treatment response. DRD4 and MAOB genotypes were linked to improved HAMD 17 scores, but the preliminary nature of the results is noted due to the limited sample size. Further research into the role of habenular dopamine D4 receptors in antidepressant response is recommended.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Psychology, Clinical
Jessica M. de Klerk-Sluis, Marloes J. Huijbers, Stephan Locke, Jan Spijker, Philip Spinhoven, Anne E. M. Speckens, Henricus G. Ruhe
Summary: The study found that cognitive reactivity (CR) and mindfulness were associated with relapse in remitted major depressive disorder (MDD) patients before the initiation of Mindfulness-based cognitive therapy (MBCT). Higher CR and lower mindfulness were found to increase the risk of relapse, while self-compassion and rumination were not associated with relapse. Particularly, for rumination, there was a significant interaction with the use of maintenance antidepressant medication, impacting its relationship with relapse.
DEPRESSION AND ANXIETY
(2022)
Article
Psychology, Clinical
Emira Deumic Shultz, James A. Mills, Vicki L. Ellingrod, Jeffrey R. Bishop, Chadi A. Calarge
Summary: In adolescents, depression is associated with lower sexual functioning while SSRI use impairs orgasm.
JOURNAL OF CLINICAL PSYCHIATRY
(2021)
Review
Medicine, General & Internal
Anna Mosiolek, Aleksandra Pieta, Slawomir Jakima, Natalia Zborowska, Jadwiga Mosiolek, Agata Szulc
Summary: Major depressive disorder is a prevalent mental illness worldwide, with more than 30% of patients not achieving remission through conventional therapy. Inflammation and disturbed neurogenesis are implicated in the pathophysiology of depression, with potential involvement of neurotrophic factors in patient recovery. The influence of antidepressants on inflammatory cytokines and neurotrophins remains inconsistent, with selective serotonin reuptake inhibitors, selective serotonin and noradrenaline inhibitors, and tricyclic antidepressants showing possible anti-inflammatory properties. Further research is needed to determine the role of inflammatory markers in predicting treatment response in MDD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Clinical Neurology
Julia J. Meerman, Sophie E. ter Hark, Joost G. E. Janzing, Marieke J. H. Coenen
Summary: This review examines the genetic overlap between various traits and antidepressant treatment response in patients with unipolar MDD using polygenic risk scores (PRS). The results suggest that PRSs for several traits, including attention-deficit hyperactivity disorder and coronary artery disease, may be associated with antidepressant treatment response. However, the studies varied in sample size and outcome measures, highlighting the need for larger cohorts and standardized assessment methods.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Medicine, General & Internal
Jian Liu, Zejun Guo, Meida Fan, Weihao Liang, Xin He, Dexi Wu, Yugang Dong, Wengen Zhu, Chen Liu
Summary: Limited data on depression in HFpEF patients and the efficacy of antidepressants. Study found no significant association between baseline major depression and cardiovascular outcomes in HFpEF patients. Treatment with antidepressants did not affect prognosis in HFpEF patients with major depression.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Psychiatry
Ivo H. Cerda, Paul J. Fitzgerald
Summary: The article presents a neurochemical model of unipolar major depressive disorder and predicts optimal pharmacological treatment based on different subtypes of depression. It suggests using different medications for high and low NE/5HT depression, and predicts the effects of rapidly acting antidepressants on different subtypes.
PSYCHIATRY RESEARCH
(2021)
Article
Clinical Neurology
Thibaut Gelle, Rayhanatou Altine Samey, Brigitte Plansont, Barbara Bessette, Marie-Odile Jauberteau-Marchan, Fabrice Lalloue, Murielle Girard
Summary: This study found that BDNF levels were decreased and proBDNF levels were increased in both serum and exosomes in patients with Major Depression (MD). During antidepressant treatment, there was an inverse relationship in the levels of BDNF and proBDNF in serum and exosomes. However, these levels were not related to clinical improvement or depression scales.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Clinical Neurology
Ya-Mei Tzeng, I-Hsun Li, Hui-Han Kao, Jui-Hu Shih, Chin-Bin Yeh, Yi-Hsien Chen, Li-Ting Kao
Summary: This study found that antidepressants can reduce the subsequent risk of psoriasis in patients with major depressive disorder, particularly selective serotonin reuptake inhibitors and low-dose antidepressants have significant protective effects.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Clinical Neurology
Chiara Fabbri, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Alessandro Serretti, Cathryn M. Lewis
Summary: Utilizing clinical risk factors to predict pharmacotherapy resistance and guide the prescription of pharmacotherapy combined with psychotherapy could be a cost-effective strategy, with CL-R showing better cost-effectiveness compared to PGx-CL-R in certain scenarios. The study suggests that using these predictors can help identify patients who are more likely to benefit from combined treatment, ultimately improving outcomes and reducing costs.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Clinical Neurology
Christine M. Ramsey, Kevin G. Lynch, Michael E. Thase, Joel Gelernter, Henry R. Kranzler, Jeffrey M. Pyne, Mei-Chiung Shih, Annjannette Stone, David W. Oslin
Summary: The study investigates the use of pharmacogenetics in patients with Major Depressive Disorder and finds that PGx testing may result in clinically significant gene-drug interactions for 20% of patients prescribed antidepressants. Patients with prior antidepressant treatment are more likely to have significant gene-drug interactions in their next intended treatment, suggesting they may benefit most from PGx testing.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Clinical Neurology
E. Papalexi, A. Galanopoulos, D. Roukas, I. Argyropoulos, I. Michopoulos, A. Douzenis, I. Gkolia, P. Fotiadis, D. Kontis, I. M. Zervas
Summary: Patients with MDD responding to antidepressant treatment still experience cognitive symptoms and functional impairment, especially in executive functioning. Concentration difficulties are common among responders. Patient-reported cognitive symptoms are significantly associated with functionality.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Psychology, Clinical
Chiara Fabbri, Julian Mutz, Cathryn M. Lewis, Alessandro Serretti
Summary: This study was the first to comprehensively evaluate the predictors of wellbeing in relation to the history of MDD. The identified variables are important to identify individuals at risk and promote wellbeing.
PSYCHOLOGICAL MEDICINE
(2023)
Editorial Material
Neurosciences
Dekel Taliaz, Alessandro Serretti
Summary: The validity of clinical trials in psychiatry has been under discussion in the past two decades. The commonly used method of randomized controlled trials (RCTs) faces challenges when applied in the psychiatric field due to strict participant criteria and inconsistency in endpoint parameters. This has led to problematic clinical practice in psychiatry.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
(2023)
Article
Psychology, Clinical
Raimondo Maria Pavarin, Chiara Fabbri, Elsa Turino, Silvia Marani, Samantha Sanchini, Diana De Ronchi
Summary: Suicide is a major global health issue, and alcohol use disorders (AUDs) are an important risk factor for suicide attempts. This study utilized electronic health records to identify individuals diagnosed with AUD in the Metropolitan area of Bologna. The results showed a higher rate of suicide attempts in this population, particularly in females, within one year of AUD diagnosis, and among patients with psychiatric comorbidities or concurrent abuse of cannabis or benzodiazepines. Additionally, the risk of suicide attempts was significantly higher in females in 2020 compared to 2019, possibly due to the COVID-19 pandemic.
JOURNAL OF PSYCHOACTIVE DRUGS
(2023)
Article
Pharmacology & Pharmacy
Vincenzo Oliva, Giuseppe Fanelli, Manuel Zamparini, Cristina Zarbo, Matteo Rocchetti, Letizia Casiraghi, Fabrizio Starace, Alessandra Martinelli, Alessandro Serretti, Giovanni de Girolamo, DiAPASon Consortium
Summary: Antipsychotic polypharmacy (APP) is commonly used in patients with schizophrenia spectrum disorders (SSDs) despite recommendations against it. This study found high rates of APP and lower levels of physical activity in both residential and outpatient patients. However, patients on APP showed trends of reduced sedentariness and higher levels of light physical activity compared to those on monopharmacy.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Review
Psychiatry
Kristina Mozuraityte, Agne Stanyte, Naomi A. Fineberg, Alessandro Serretti, Julija Gecaite-Stonciene, Julius Burkauskas
Summary: This study conducted a scoping review of published literature to examine the relationship between mental fatigue and various psychiatric disorders. The findings suggest that mental fatigue is studied in mood disorders, anxiety disorders, obsessive-compulsive disorder, and obsessive-compulsive personality disorder. Cognitive factors such as unhelpful beliefs about sleep and symptom-focussed rumination, as well as personality risk factors, were found to be relevant in predicting mental fatigue symptoms. Further investigation is needed to explore mental fatigue in adult psychiatric samples.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
(2023)
Article
Psychiatry
Fabio Panariello, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Alessandro Serretti, Chiara Fabbri
Summary: This study aimed to identify factors associated with side effects of psychotropic drugs in a real-world setting enriched with treatment-resistant depression (TRD) patients. Results showed that the severity of depressive symptoms was associated with total, psychic, and neurological side effects, while autonomic side effects were higher in patients with somatic comorbidities and lower in patients receiving trazodone. Multivariate analyses revealed that depressive symptom severity was associated with psychic and total side effects, generalized anxiety disorder (GAD) with neurological side effects, and somatic comorbidities remained associated with autonomic side effects. Trazodone was associated with lower side effects and with augmentation treatments. Augmentation therapies showed opposite effects depending on response status, i.e. increased or decreased the risk of side effects in responders and non-responders/resistant patients, respectively.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
(2023)
Article
Pharmacology & Pharmacy
Laura Mandelli, Yuri Milaneschi, Sarah Hiles, Alessandro Serretti, Brenda W. Penninx
Summary: An unhealthy lifestyle plays a crucial role in the development and progression of chronic disorders, and it may also affect biological systems involved in stress response. Using data from the Netherlands Study of Depression and Anxiety, researchers calculated a global index of unhealthy lifestyle based on five self-reported habits. They found that the index was associated with hyperactivity of the hypothalamus-pituitary-adrenal axis and increased inflammation, indicating that unhealthy habits increase biological stress. The use of drugs also impacted the autonomic nervous system activity.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Editorial Material
Pharmacology & Pharmacy
Alessandro Serretti
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Editorial Material
Pharmacology & Pharmacy
Alessandro Serretti
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Vincenzo Oliva, Giuseppe Fanelli, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Chiara Fabbri, Alessandro Serretti
Summary: This study found that different clinical subtypes of major depressive disorder (MDD), particularly melancholic features and typical neurovegetative symptoms, may be associated with distinct underlying genetics. These findings contribute to a better understanding of the genetic heterogeneity of MDD.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Editorial Material
Pharmacology & Pharmacy
Paolo Olgiati, Alessandro Serretti
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Editorial Material
Pharmacology & Pharmacy
Alessandro Serretti
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Article
Chemistry, Analytical
Jaime Millan-Santiago, Rosalba Vitagliano, Fortunata Mondella, Roberto Mandrioli, Roccaldo Sardella, Rafael Lucena, Tomaz Vovk, Soledad Cardenas, Federico Boaron, Alessandro Serretti, Carmine Petio, Michele Protti, Laura Mercolini
Summary: In this study, a bioanalytical method using volumetric absorptive microsampling (VAMS) was developed and validated for therapeutic drug monitoring (TDM) of psychiatric patients under cariprazine treatment. The VAMS-UHPLC-MS methodology showed satisfactory results and was proven to be a useful alternative to cariprazine plasma analysis in clinical practice.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2023)
Article
Psychiatry
Alexander Kautzky, Lucie Bartova, Gernot Fugger, Markus Dold, Daniel Souery, Stuart Montgomery, Joseph Zohar, Julien Mendlewicz, Chiara Fabbri, Alessandro Serretti, Dan Rujescu, Siegfried Kasper
Summary: This study investigates the differences in presentation and treatment outcomes of treatment-resistant depression (TRD) among different age groups. It finds that age has an impact on depressive symptoms and treatment outcomes. In TRD patients, symptom load and hospitalization time increase with age, while treatment responders do not show this trend. Older patients are more likely to have symptoms such as inner tension, reduced appetite, concentration difficulties, and lassitude.
EUROPEAN PSYCHIATRY
(2023)